Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Mellitus Progression Clear all
Enrolling by invitation Not applicable Interventional

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

NCT05514184
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions
PLAFOND diet
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Orange, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Phase 4 Interventional

Semaglutide Treatment On Coronary Progression

NCT03985384
View directory record Official record
Conditions
Type 2 Diabetes, Coronary Artery Disease
Interventions
Semaglutide 2 MG/1.5 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 16, 2026, 4:16 PM EDT
Recruiting No phase listed Observational

Rare and Atypical Diabetes Network

NCT05544266
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Not applicable Interventional

Assessing Effectiveness of a Diabetes Navigator in Increasing Progression of Advanced Diabetes Technologies

NCT06229236
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Navigator
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

NCT00529399
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 16, 2026, 4:16 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

NCT02681809
View directory record Official record
Conditions
Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
Interventions
ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Phoenix, Arizona • Campbell, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 16, 2026, 4:16 PM EDT
Recruiting Phase 2 Interventional

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

NCT07216391
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Antithymocyte Globulin (ATG), Teplizumab
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 34 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stop Atherosclerosis in Native Diabetics Study

NCT00147251
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes, Carotid Atherosclerosis
Interventions
FDA approved drugs to treat blood pressure and cholesterol
Drug
Lead sponsor
Cynthia West
Other
Eligibility
40 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 16, 2026, 4:16 PM EDT
Recruiting Phase 4 Interventional

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859
View directory record Official record
Conditions
Type II Diabetes, Atherosclerosis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Matthew J. Budoff
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 16, 2026, 4:16 PM EDT
Completed No phase listed Observational

Delaying the Progression of Diabetic Nephropathy in Pima Indians

NCT00353600
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Phase 2 Interventional

Prevention of Diabetes Progression Trial (PDPT)

NCT00198146
View directory record Official record
Conditions
Newly Diagnosed With Type 1 Diabetes
Interventions
Zenapax
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 16, 2026, 4:16 PM EDT
Not yet recruiting Phase 3 Interventional

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579
View directory record Official record
Conditions
Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
79
States / cities
Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 16, 2026, 4:16 PM EDT
Withdrawn Phase 2 Interventional

Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children

NCT01561508
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
gamma-amino-butyric acid, Xylitol
Drug · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Sep 16, 2026, 4:16 PM EDT
Recruiting Phase 1 Interventional

Prevention of Progression of Prediabetes, Obesity and CV Risk

NCT06446531
View directory record Official record
Conditions
Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Interventions
Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin, Actos
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 16, 2026, 4:16 PM EDT
Not yet recruiting Phase 2 Interventional

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

NCT07683026
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Golimumab, Placebo (matching golimumab)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years to 44 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Phase 4 Interventional

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

NCT00174824
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 70 Years
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Sep 16, 2026, 4:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Role of KATP Channel Loss in Type 2 Diabetes

NCT06830096
View directory record Official record
Conditions
Obesity and Type 2 Diabetes
Interventions
10 mg glipizide ingestion
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 16, 2026, 4:16 PM EDT
Completed No phase listed Observational

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

NCT04477707
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Finerenone (BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 16, 2026, 4:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Risk Progression in Normal and Diabetic Control Subjects.

NCT00579228
View directory record Official record
Conditions
Diabetes, Inflammation
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 16, 2026, 4:16 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

NCT00891995
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed loop, Home glucose monitoring, Insulin pump, Continuous glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Not applicable Interventional Results available

Metatarsal Phalangeal Joint Deformity Progression - R01

NCT02616263
View directory record Official record
Conditions
Diabetes Mellitus (DM)
Interventions
Foot exercise, Shoulder exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 16, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

NCT02540993
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
176
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 16, 2026, 4:16 PM EDT
Not listed Phase 4 Interventional

Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

NCT02162550
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Bydureon, placebo
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
21 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 16, 2026, 4:16 PM EDT